Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Tech

 Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025 -

- Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs -

- Zentalis to receive up-front payment of $35 million in cash and Immunome common stock and is eligible to receive up to $275 million of milestone payments and mid-to-high single-digit royalties -

https://www.businesswire.com/news/home/20240108297637/en/